Menu
← Oncology Approval Tracker
FDA DECISION ·
Jubereq
denosumab-desu · Accord BioPharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Xgeva biosimilar for preventing skeletal complications in multiple myeloma or solid tumor bone metastases, treating giant cell tumor of bone in eligible adults and skeletally mature adolescents, and treating malignancy-related hypercalcemia refractory to bisphosphonates.
LAMPGEN ANALYSIS
Why it matters
This oncology-dose denosumab approval adds a biosimilar option for the labeled Xgeva uses.
What research teams should watch
Train staff to verify the intended reference and measure renal and mineral risk according to the relevant label.
PRIMARY RECORDS